Filtered By:
Specialty: Drugs & Pharmacology
Procedure: Percutaneous Coronary Intervention
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 122 results found since Jan 2013.
Contemporary Implications of ECG to Activation Time on Long-term Outcomes in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention
This study evaluates the association of EAT with major adverse cardiovascular events (MACEs) in more contemporary patients undergoing PPCI and investigates factors that influence EAT.METHODS: A total of 1082 consecutive patients with STEMI who underwent PPCI from 2013 to 2019 were classified into 3 groups according to EAT: EAT ≤30 minutes, EAT of 30 to 60 minutes, and EAT >60 minutes. We analyzed the incidence of MACEs, including all-cause death, nonfatal recurrence of MI, or nonfatal stroke during a median follow-up of 37 months.FINDINGS: The median EAT was 58 minutes (interquartile range, 44-80 minutes), which expla...
Source: Clinical Therapeutics - November 9, 2021 Category: Drugs & Pharmacology Authors: Hui Gao Hui Peng Zhijun Sun Hui Chen Beibing Di Hongwei Li Source Type: research
The Impact of Urate-Lowering Therapy in Post-Myocardial Infarction Patients: Insights from a Population-Based, Propensity Score-Matched Analysis
Clin Pharmacol Ther. 2021 Oct 31. doi: 10.1002/cpt.2473. Online ahead of print.ABSTRACTThe role of urate-lowering therapy (ULT) for the primary prevention of cardiovascular events has been widely discussed, but its evidence for the secondary prevention of myocardial infarction (MI) is limited. Therefore, we conduct a population-based, propensity score-matched cohort study to investigate the cardiovascular outcomes among post-MI patients with and without ULT. A total of 19,042 newly diagnosed in-hospital MI patients were selected using the Taiwan National Health Insurance Database between 1 January 2005 and 31 December 2016...
Source: Clinical Pharmacology and Therapeutics - October 31, 2021 Category: Drugs & Pharmacology Authors: Chi-Jung Tai Chin-Chung Wu Kun-Tai Lee Tzyy-Guey Tseng Hui-Chun Wang Fang-Rong Chang Yi-Hsin Yang Source Type: research
Incidence and Risk Factors for Antiplatelet Therapy –Related Bleeding Complications Among Elderly Patients After Coronary Stenting: A Multicenter Retrospective Observation
Conclusion: A higher PRECISE-DAPT score of 33 might be a more reasonable cutoff value for predicting BARC ≥2 type bleeding risk in CAD patients (≥75 years). In addition, the history of hemorrhagic stroke, peptic ulcer, and myocardial infarction were identified as the risk factors of BARC ≥2 type bleeding events.
Source: Frontiers in Pharmacology - July 30, 2021 Category: Drugs & Pharmacology Source Type: research
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in high-bleeding-risk patients with acute coronary syndrome in contemporary practice
CONCLUSIONS: The treatment of bivalirudin showed better efficacy and safety as compared to UFH among patients with ACS undergoing PCI at high risk of bleeding in contemporary practice.PMID:34321166 | DOI:10.1016/j.biopha.2020.110758
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - July 29, 2021 Category: Drugs & Pharmacology Authors: Yahao Zhang Yanghui Zhang Zhiyu Liu Bin Zhang Guizhi Liu Kui Chen Source Type: research
Effects of aging on clinical outcomes in patients receiving genotype ‐guided P2Y12 inhibitor selection after percutaneous coronary intervention
ConclusionThis study suggests important clinical benefits ofCYP2C19 genotype-guided antiplatelet therapy after PCI in both younger and older patients.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - July 21, 2021 Category: Drugs & Pharmacology Authors: Brian Wood,
Craig R. Lee,
Ian R. Mulrenin,
Megan N. Gower,
Joseph S. Rossi,
Karen E. Weck,
George A. Stouffer Tags: TI on Advances in Cardiovascular Pharmacotherapy Source Type: research
Effects of Aging on Clinical Outcomes in Patients Receiving Genotype ‐Guided P2Y12 Inhibitor Selection after Percutaneous Coronary Intervention
ConclusionThis study suggests important clinical benefits ofCYP2C19 genotype-guided antiplatelet therapy after PCI in both younger and older patients.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - July 10, 2021 Category: Drugs & Pharmacology Authors: Brian Wood,
Craig R. Lee,
Ian R. Mulrenin,
Megan N. Gower,
Joseph S. Rossi,
Karen E. Weck,
George A. Stouffer Tags: ORIGINAL RESEARCH Source Type: research
Comparative Effectiveness and Safety of Prasugrel versus Ticagrelor following Percutaneous Coronary Intervention: An Observational Study
ConclusionWhen compared with ticagrelor, prasugrel use following PCI for ACS was associated with a lower risk of death, MI, or stroke, as well as a reduced risk of major bleeding.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 1, 2021 Category: Drugs & Pharmacology Authors: Nicholas Belviso,
Herbert D. Aronow,
Richard Wyss,
Marilyn Barbour,
Yichi Zhang,
Xuerong Wen,
Stephen Kogut Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Serum Free Triiodothyronine and the Responsiveness to Clopidogrel in Patients Undergoing Elective Percutaneous Coronary Intervention
ConclusionsLow FT3 was independently associated with increased risks of both low responsiveness to clopidogrel and cardiovascular events in patients undergoing elective PCI.
Source: Advances in Therapy - April 29, 2021 Category: Drugs & Pharmacology Source Type: research
Efficacy and Safety of Bivalirudin During Percutaneous Coronary Intervention in Chronic Total Occlusion: A Retrospective Study
The objective of this study was to examine the efficacy and safety of bivalirudin during percutaneous coronary intervention (PCI) in patients with CTO.METHODS: This trial used a retrospective cohort study design. Medical information from 736 patients with CTO who underwent PCI with bivalirudin or UFH at the First Affiliated Hospital of Zhengzhou University from July 2019 to September 2020 was extracted and analyzed. The primary end point was the 30-day incidence of net adverse clinical events (NACEs), and the secondary end point was the major adverse cardiovascular events (MACEs), which were related to safety and efficacy,...
Source: Clinical Therapeutics - April 3, 2021 Category: Drugs & Pharmacology Authors: Yanghui Zhang Yahao Zhang Chao Chang Shumei Yan Zheng Chen Lishuai Zhang Kui Chen Guizhi Liu Source Type: research
Optimal duration and combination of antiplatelet therapies following percutaneous coronary intervention: A systematic review and meta-analysis
CONCLUSION: DAPT may be shortened to 3 months in patients with low ischemic risk but high bleeding risk, whereas it may be extended to >12 months in case of high ischemic and low bleeding risk. The concept of P2Y12 inhibitor monotherapy, although promising, needs to be challenged.PROSPERO REGISTRATION NO: CRD42020163719.PMID:33753284 | DOI:10.1016/j.vph.2021.106858
Source: Vascular Pharmacology - March 23, 2021 Category: Drugs & Pharmacology Authors: Georg Gelbenegger Ummahan Erari-Canyurt J ürgen Grafeneder Bernd Jilma Maciej Lesiak Anna Komosa Raffaele de Caterina Marek Postula Jolanta M Siller-Matula Source Type: research
